2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases

P2.09. Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the efficacy and safety of furmonertinib as a first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases. Furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has shown effectiveness in EGFR-mutated NSCLC patients. The study included 18 patients with EGFR-mutated NSCLC and brain metastases who received furmonertinib 160mg orally once daily. The primary endpoint was CNS progression-free survival, and secondary endpoints included objective response rate, disease control rate, overall survival, and adverse events.<br /><br />The study found that furmonertinib showed promising efficacy in these patients. The objective response rate and disease control rate were 77.8% and 100%, respectively. The CNS objective response rate was 88.9%. Patients with EGFR exon 19 deletion had a higher CNS objective response rate compared to patients with L858R mutation. The median best percentage change of CNS target lesions from baseline was -67.95%. The one-year progression-free survival, CNS progression-free survival, and overall survival rates were 92.9%, 92.9%, and 100%, respectively.<br /><br />Furmonertinib was well tolerated, with diarrhea and rash being the most common treatment-related adverse events. Grade 3 or higher adverse events occurred in only one patient, and dose reductions were reported in two patients. No treatment interruptions, discontinuations, or deaths were attributed to adverse events.<br /><br />In conclusion, furmonertinib 160mg orally once daily showed encouraging efficacy and safety as a first-line therapy for EGFR-mutated NSCLC patients with CNS metastases. These findings suggest that furmonertinib has the potential to be an effective treatment option for this patient population. The study was supported by grants from the National Natural Science Foundation of China and Beijing Xisike Clinical Oncology Research Foundation.

Asset Subtitle

Xixi Zheng

Meta Tag

Speaker Xixi Zheng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

furmonertinib

first-line therapy

NSCLC

CNS metastases

efficacy

safety

EGFR-mutated

objective response rate

disease control rate

adverse events